Dietz A, Wichmann G, Wiegand S. [Update Treatment HPV-16-positive Oropharyngeal Carcinoma].
Laryngorhinootologie 2021;
100:832-844. [PMID:
34614529 DOI:
10.1055/a-1523-9045]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND
Oropharynx carcinoma (OPSCC) is a genetically heterogeneous tumor group with high prognostic diversity due to its worldwide increase in incidence and the association with the human papillomavirus HPV 16, but also chronic tobacco/alcohol consumption.
OBJECTIVE
The review attempts to present the current view on therapy and prevention of OPSCC with respect to association with HPV 16.
MATERIAL & METHODS
The overview is based on the current relevant literature as well as current studies.
RESULTS & DISCUSSION
The OPSCC presents itself as a very complex, genetically heterogeneous group of head and neck tumors, which should therefore be considered in detail. The currently contradictory trial situation of retrospective studies versus prospective trials, the current TNM classification (8th edition) and the scarce prospective data arguing for non-inferiority of therapy de-intensification attempts currently admonish to encourage a more conservative treatment.
Collapse